| Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025 |
Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dualinhibitor of PDE3 and PDE4 for a broad COPD population |
globenewswire.com |
2025-05-06 10:00:00 |
Czytaj oryginał (ang.) |
| Silencing The Doubters: Verona Pharma Could Be Sitting On A Blockbuster |
VRNA's COPD drug Ohtuvayre shows impressive Q1'25 net sales of $71.3M in just its third quarter of sales, all but confirming the blockbuster future of the drug. Ongoing R&D and trials, including a phase 3 trial in China that should readout in Q2'25, represent future clinical catalysts. A partnership in the UK or Europe is another potential near-term catalyst, although if the terms are not favorable, that could impact the performance of the stock. |
seekingalpha.com |
2025-05-01 12:51:20 |
Czytaj oryginał (ang.) |
| Verona Pharma plc (VRNA) Q1 2025 Earnings Call Transcript |
Verona Pharma plc (NASDAQ:VRNA ) Q1 2025 Earnings Conference Call April 29, 2025 9:00 AM ET Company Participants Victoria Stewart - Senior Director, Investor Relations and Communications David Zaccardelli - President and CEO Mark Hahn - CFO Christopher Martin - CCO Tara Rheault - Chief Development Officer Kathleen Rickard - Chief Medical Officer Conference Call Participants Andrew Tsai - Jefferies Yasmeen Rahimi - Piper Sandler Olivia Brayer - Cantor Fitzgerald Tara Bancroft - TD Cowen Tiago Fauth - Wells Fargo Thomas Shrader - BTIG Ram Selvaraju - HCW Sushila Hernandez - Van Lanschot Kempen Boobalan Pachaiyappan - ROTH Operator Welcome to Verona Pharma's First Quarter 2025 Financial Results and Operating Highlights Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-04-29 19:45:55 |
Czytaj oryginał (ang.) |
| Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update |
Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre ® net sales of $71.3 million (+95% vs Q4 2024) |
globenewswire.com |
2025-04-29 10:00:00 |
Czytaj oryginał (ang.) |
| Verona Pharma's Bull Case Holds, But Lifecycle Extension Is Critical |
Ohtuvayre's robust launch for COPD treatment exceeded expectations, with Q4 revenue of $36.6 million and FY24 revenue of $42.3 million, indicating strong market demand. Verona's financial health is solid with $399.757 million in cash, providing a cash runway into 2028, despite a net loss of $33.8 million in Q4. Verona is extending Ohtuvayre's life cycle through new formulations and fixed-dose combinations, aiming for cash flow break-even with a quarterly run rate near $300 million. |
seekingalpha.com |
2025-04-07 14:47:15 |
Czytaj oryginał (ang.) |
| Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS |
RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional $200 million LONDON and RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, has amended its existing strategic financing agreements by repaying the revenue interest purchase and sale agreement (“RIPSA”) and increasing the debt facility to $450 million on improved terms with funds managed by Oaktree Capital Management, L.P. |
globenewswire.com |
2025-03-28 09:00:00 |
Czytaj oryginał (ang.) |
| Verona Pharma plc (VRNA) Q4 2024 Earnings Call Transcript |
Verona Pharma plc (NASDAQ:VRNA ) Q4 2024 Earnings Conference Call February 27, 2024 9:00 AM ET Company Participants David Zaccardelli - President and CEO Mark Hahn - CFO Christopher Martin - CCO Conference Call Participants Andrew Tsai - Jefferies Yasmeen Rahimi - Piper Sandler Tiago Fauth - Wells Fargo Tom Shrader - BTIG Ram Selvaraju - HCW Joon Lee - Truist Boobalan Pachaiyappan - ROTH Operator Good morning ladies and gentlemen. Welcome to the Verona Pharma Fourth Quarter and Full Year 2024 Financial Results and Conference Call. |
seekingalpha.com |
2025-02-27 16:31:21 |
Czytaj oryginał (ang.) |
| Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update |
Ohtuvayre TM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 |
globenewswire.com |
2025-02-27 08:00:00 |
Czytaj oryginał (ang.) |
| Verona Pharma Announces March 2025 Investor Conference Participation |
LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in March 2025: |
globenewswire.com |
2025-02-18 08:00:00 |
Czytaj oryginał (ang.) |
| Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update |
LONDON and RALEIGH, N.C., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth quarter and full year ended December 31, 2024 on Thursday, February 27, 2025 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update. |
globenewswire.com |
2025-02-13 08:00:00 |
Czytaj oryginał (ang.) |
| What Makes Verona Pharma (VRNA) a Good Fit for 'Trend Investing' |
If you are looking for stocks that are well positioned to maintain their recent uptrend, Verona Pharma (VRNA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. |
zacks.com |
2025-02-12 11:51:13 |
Czytaj oryginał (ang.) |
| Here's Why 'Trend' Investors Would Love Betting on Verona Pharma (VRNA) |
Verona Pharma (VRNA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. |
zacks.com |
2025-01-27 11:56:40 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 30.65% Upside in Verona Pharma (VRNA): Can the Stock Really Move This High? |
The average of price targets set by Wall Street analysts indicates a potential upside of 30.7% in Verona Pharma (VRNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-01-14 12:56:10 |
Czytaj oryginał (ang.) |
| Verona Pharma (VRNA) Upgraded to Buy: What Does It Mean for the Stock? |
Verona Pharma (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-01-10 15:01:29 |
Czytaj oryginał (ang.) |
| Verona Pharma (VRNA) is on the Move, Here's Why the Trend Could be Sustainable |
If you are looking for stocks that are well positioned to maintain their recent uptrend, Verona Pharma (VRNA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. |
zacks.com |
2025-01-10 12:02:10 |
Czytaj oryginał (ang.) |
| Verona Pharma's Ohtuvayre Defies Expectations In Q4, But Stock Alpha May Now Be Limited |
Verona Pharma's Ohtuvayre, a novel COPD treatment, achieved $36 million in Q4 sales, indicating strong market interest and unmet need for new therapies. Despite aggressive pricing, Ohtuvayre's broad label and significant prescriber uptake suggest potential for higher-than-expected peak annual sales. Verona Pharma holds $336 million in cash, projecting operational funding through at least the end of 2026. |
seekingalpha.com |
2025-01-08 15:45:57 |
Czytaj oryginał (ang.) |
| Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights |
Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively |
globenewswire.com |
2025-01-07 08:00:00 |
Czytaj oryginał (ang.) |
| Verona Pharma Announces December 2024 Investor Conference Participation |
LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in December 2024: |
globenewswire.com |
2024-11-19 04:00:00 |
Czytaj oryginał (ang.) |
| Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value |
Verona Pharma has seen its share price skyrocket in anticipation of the commercial launch of its COPD treatment. |
cnbc.com |
2024-11-09 10:23:10 |
Czytaj oryginał (ang.) |
| Verona Pharma to Present at Jefferies London Healthcare Conference |
LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 6:30 a.m. ET / 11:30 a.m. GMT. |
globenewswire.com |
2024-11-05 04:00:00 |
Czytaj oryginał (ang.) |
| Verona Pharma plc (VRNA) Q3 2024 Earnings Call Transcript |
Verona Pharma plc (NASDAQ:VRNA ) Q3 2024 Earnings Conference Call November 4, 2024 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Officer Christopher Martin - Chief Commercial Officer Tara Rheault - Chief Development Officer Conference Call Participants Andrew Tsai - Jefferies Yasmeen Rahimi - Piper Sandler. Raghuram Selvaraju - HC Wainwright Tom Shrader - BTIG Edward Thomason - VLK Joon Lee - Truist Boobalan Pachaiyappan - Roth Capital Partners Operator Good morning, everyone, and welcome to Verona Pharma's Third Quarter 2024 Financial Results and Operating Highlights Conference Call. |
seekingalpha.com |
2024-11-04 13:47:31 |
Czytaj oryginał (ang.) |
| Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update |
Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 |
globenewswire.com |
2024-11-04 04:00:00 |
Czytaj oryginał (ang.) |
| Recent Price Trend in Verona Pharma (VRNA) is Your Friend, Here's Why |
Verona Pharma (VRNA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
zacks.com |
2024-10-25 13:51:27 |
Czytaj oryginał (ang.) |
| 5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright |
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, BPMC, CRSP, FOLD and VRNA well in this volatile sector. |
zacks.com |
2024-10-24 14:11:17 |
Czytaj oryginał (ang.) |
| Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update |
LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. GMT to discuss these financial results and provide a corporate update. |
globenewswire.com |
2024-10-21 06:00:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Verona Pharma (VRNA) Could Surge 25.25%: Read This Before Placing a Bet |
The average of price targets set by Wall Street analysts indicates a potential upside of 25.3% in Verona Pharma (VRNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-10-11 14:56:29 |
Czytaj oryginał (ang.) |
| Verona Pharma (VRNA) Is a Great Choice for 'Trend' Investors, Here's Why |
Verona Pharma (VRNA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. |
zacks.com |
2024-10-09 13:50:31 |
Czytaj oryginał (ang.) |
| Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024 |
Verona Pharma announces four oral presentations and two posters on analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) at CHEST 2024. |
globenewswire.com |
2024-09-30 06:00:00 |
Czytaj oryginał (ang.) |
| Verona Pharma's Ohtuvayre Set To Unlock Significant Value In COPD Care |
Verona Pharma's Ohtuvayre (ensifentrine) was approved for COPD in June 2024, introducing a novel dual mechanism of action. Ohtuvayre is priced at $2,950 per month, significantly above ICER's cost-effectiveness benchmark of $7,500–$12,700 annually. The drug targets patients who experience exacerbations despite traditional triple therapy (LABA, LAMA, ICS), addressing an unmet need in COPD treatment. |
seekingalpha.com |
2024-09-14 08:20:00 |
Czytaj oryginał (ang.) |
| Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024 |
Verona Pharma presents one oral presentation and 3 posters on additional analyses from its successful Phase 3 ENHANCE studies with Ohtuvayre at ERS 2024. |
globenewswire.com |
2024-09-05 06:00:00 |
Czytaj oryginał (ang.) |
| Top 3 Health Care Stocks That May Crash In August |
As of Aug 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. |
benzinga.com |
2024-08-14 12:35:02 |
Czytaj oryginał (ang.) |
| Verona Pharma plc (VRNA) Q2 2024 Earnings Call Transcript |
Verona Pharma plc (NASDAQ:VRNA ) Q2 2024 Earnings Conference Call August 8, 2024 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Officer Christopher Martin - Chief Commercial Officer Tara Rheault - Chief Development Officer Conference Call Participants Andrew Tsai - Jefferies Group LLC Thomas Shrader - BTIG, LLC Raghuram Selvaraju - H.C. Wainwright & Co. Edward Thomason - Van Lanschot Kempen Operator Welcome to Verona Pharma's Second Quarter 2024 Financial Results and Operating Highlights Conference Call. |
seekingalpha.com |
2024-08-08 17:15:30 |
Czytaj oryginał (ang.) |
| Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update |
Ohtuvayre TM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. |
globenewswire.com |
2024-08-08 06:00:00 |
Czytaj oryginał (ang.) |
| Verona Pharma to Present at 44th Annual Canaccord Growth Conference |
LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the 44th Annual Canaccord Growth Conference on Tuesday, August 13, 2024, at 1:30 p.m. EDT / 6:30 p.m. BST. |
globenewswire.com |
2024-07-30 06:00:00 |
Czytaj oryginał (ang.) |
| Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update |
LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the second quarter ended June 30, 2024 on Thursday, August 8, 2024 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update. |
globenewswire.com |
2024-07-25 06:00:00 |
Czytaj oryginał (ang.) |
| Verona (VRNA) Stock Surges 36% in the Past Month: Here's Why |
Verona Pharma (VRNA) surges on the recent FDA approval for its lead drug, which is the first inhaled COPD product with a novel mechanism of action in more than 20 years. |
zacks.com |
2024-07-12 16:12:05 |
Czytaj oryginał (ang.) |
| Verona Pharma Is Launching Ohtuvayre, Although There Will Be Competition |
VRNA received FDA approval for ensifentrine (Ohtuvayre) for the maintenance treatment of COPD on June 26. SNY/REGN's Dupixent represents a potential competitor. As do other drugs in development from SNY/REGN and GSK. Verona has the potential for further growth beyond the current approval, although in the near-term, initial sales seem likely to be a major determinant of the stock's direction. |
seekingalpha.com |
2024-06-30 13:00:00 |
Czytaj oryginał (ang.) |